In Stock Cell Lines
Homo sapiens (Human)
Blood (peripheral blood)
Suspension
The PANX1 Knockout Jurkat Cell Line is a CRISPR/Cas9-edited human T lymphocyte model with targeted disruption of the PANX1 gene, which encodes an ATP-permeable channel. PANX1 channels mediate release of ATP in response to stimuli such as P2X7 receptor activation or caspase cleavage, feeding into purinergic signaling and NLRP3 inflammasome pathways. Derived from the Jurkat acute T cell leukemia line, this knockout tool enables investigation of ATP-dependent intercellular communication in T cell activation, apoptosis, and leukemogenesis. It is suited for ATP release assays, calcium flux measurements, flow cytometry, and drug screening for purinergic modulators.
LBR Knockout jurkat Polyclonal Cells
Cat. No. ARG13225
NUBPL Knockout Hela Polyclonal Cells
Cat. No. ARG8280
AMOTL1 Knockout Hela Polyclonal Cells
Cat. No. ARG20814
BRWD1 Knockout A2780 Polyclonal Cells
Cat. No. ARG28923
ENDOD1 Knockout NCI-H1299 Polyclonal Cells
Cat. No. ARG17854
FLNA Knockout CAL27 Polyclonal Cells
Cat. No. ARG11492
The PANX1 Knockout Jurkat Cell Line is a CRISPR/Cas9-edited knockout cell line derived from the Jurkat human T lymphocyte line, engineered to disrupt the PANX1 gene. This loss-of-function model enables precise interrogation of pannexin-1-mediated ATP release and downstream signaling in a leukemic T cell background. By eliminating PANX1 expression, researchers can dissect its contributions to purinergic communication, inflammasome activation, and apoptosis regulation without confounding endogenous channel activity.
The Jurkat cell line is an extensively characterized model of acute T cell leukemia, widely employed to study T cell receptor signaling, activation-induced cell death, and leukemogenesis. Its rapid growth and ease of transfection make it ideal for CRISPR/Cas9 gene targeting. The PANX1 knockout variant retains the core attributes of the parental line while ablating a key mediator of intercellular communication, offering a controlled system to examine ATP-dependent autocrine and paracrine loops.
Pannexin-1 (PANX1) forms large-pore plasma membrane channels that open in response to cellular stress, mechanical stretch, caspase-3/7 cleavage, or P2X7 receptor activation, facilitating the release of ATP and other metabolites. Extracellular ATP engages P2 purinergic receptors, triggering calcium mobilization and downstream cascades. PANX1 also interacts with the NLRP3 inflammasome and actin cytoskeleton, coupling purinergic signals to interleukin-1?? maturation and pyroptotic cell death. Within this network, PANX1 functions downstream of P2X7 and caspase-3/7, and upstream of the NLRP3?Ccaspase-1 axis, placing it at a signaling nexus linking mechanical cues, immune activation, and programmed cell death.
In Jurkat T cells, PANX1-mediated ATP release modulates activation thresholds, apoptosis susceptibility, and inflammatory responses, processes often dysregulated in leukemia. This knockout line enables dissection of PANX1??s role in T cell receptor?Cpurinergic crosstalk, and provides a platform to study how ATP efflux influences leukemic cell survival and immune evasion. Additionally, the model is relevant for elucidating mechanisms underlying metastatic cancer and ischemia-reperfusion injury, where pannexin channels contribute to pathological inflammation.
Typical applications include ATP release measurements via luciferase-based assays, calcium flux analysis with Fluo-4, annexin V binding for apoptosis quantification, flow cytometric profiling of activation markers, and western blotting for caspase activation. Co-immunoprecipitation studies with P2X7 can probe protein interactions. Researchers use this model to screen purinergic-modulating compounds, investigate inflammasome regulation, and explore fundamental T cell biology. For further information, please contact Ascent Research.
